Also in this playlist...
This transcript is automatically generated
At this possible medical breakthrough this is really important.
In the fight against breast cancer.
-- according to a study conducted at Duke University a drug approved in Europe.
To treat osteoporosis it's now been shown not only to -- cancer causing cells it may actually eliminate them altogether.
A doctor Donald McDonnell he is professor and chairman of the department of pharmacology and cancer biology at duke university school of medicine thank you for joining us.
I'll thank you very much have -- speak about our research but so let us know how was this drug discovered to begin -- Well it's kind of interest and we have been -- it in estrogen receptor which is a major target and breast cancer for years.
It's the primary target of all of that most of therapies out there for breast cancer.
We realize that -- in late stage disease of the estrogen recent there remains a target even though classical therapies have failed.
And so what we decided you was rather than wait around to discover brand new drugs which go back and look at drugs have been sitting in the drawers for the last ten or fifteen years.
I'm reading made Iraq rather remarkable surprise that a drug which has recently been approved in Europe has all the characteristics of the drug that we really want to treat and stage breast cancer.
What is the name of the drug doctor and which -- breast cancer patients would benefit the most from it.
Correct so the drug is a -- it's called -- -- offend.
At -- at trade name it was developed by Pfizer pharmaceuticals for the treatment of osteoporosis.
And what we ended up finding was is that it would be very useful for patients who have failed standard.
And it can therapy so patients who have maybe progressed on the standard drug which is either Tamoxifen or an aroma taste and -- there.
And in previous -- often now what really is being considered is that at the end of this therapy a woman had to go want to classical side of toxic chemotherapy.
And this type of drug which actually destroys the estrogen receptor and has been a holy Grail and it was sitting there all time.
So doctor Madonna what is next for the drug what happens next you know in terms of its use at this base -- -- -- -- Yes so first of all as a said the drug has been approved for osteoporosis in Europe.
And so we clinical at best and that's exciting because near term clinical trials are -- near term clinical use of this drug it's possible.
I do know that the drug is up in front of the FDA for registration for osteoporosis.
-- -- we're hoping that after this exciting data that we've just recently published.
That the -- -- of the drug would be encouraged to test this in trials of late stage breast cancer.
So it is understated his osteoporosis drug not really intended originally for breast cancer it attacks -- estrogen.
We're sector which she's you know a critical component that leads to breast cancers so.
Or there's some other drugs that also hit the -- here.
Yet so so all -- all and have been therapies like Tamoxifen or their relatives inhibitors they actually hit the estrogen -- in different ways.
What this drug does though is rob in just blocking the action of the effigy interceptor it totally -- -- -- it takes it out of the equation completely different.
There are are there is one drug on the market that is approved -- full restaurant that does the same thing.
The problem with that is is that it's a great drug in theory but it's pharmaceutical properties have really limited its use.
This -- -- ducks offense is an orally by available drunk it's not plastic Coke is -- you know outside of toxic chemotherapy.
It's just another and have been therapy in the next you know stage in the treatment of a chronic disease now.
Yes and doctor McDonald just discounting your voice your expression you seem very very hopeful no doubt about breast cancer patients -- sitting at home watching this.
Are hopeful to you know how can they get involved in some of these trials and what can they do if they want to find out more information and talk to their doctor.
I assume cells so -- -- the issue right now is of course is that the drug is approved as -- told you in Europe for osteoporosis.
I I I expected to be approved in the United States for osteoporosis.
I what we're hoping is -- that when the pharmaceutical company digest the information.
From our love and -- to allow the showing the same thing that they'll be moved to do clinical trials very quickly in late stage breast cancer.
All right doctor Donald -- congratulations.
At at duke they're one of the great universities and research facilities is well.
On this incredible discovery giving a lot of people great help thanks for being with us to share the new information -- -- and thank you very much for covering the story thank.
Filter by section